Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12308627 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2TSHRCYP3A4CYP2C19 | |
| SCHEMBL17327617 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2TSHRL3MBTL1RECQL | |
| SCHEMBL12448233 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2USP2TSHRCYP3A4CYP2C19 | |
| SCHEMBL8489683 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2TSHRL3MBTL1MEN1 | |
| SCHEMBL8489677 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2TSHRPKML3MBTL1 | |
| SCHEMBL8749065 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2TSHRL3MBTL1RECQL | |
| SCHEMBL7604321 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2TSHRL3MBTL1RECQL | |
| SCHEMBL29317762 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2TSHRCYP3A4CYP2C19 | |
| SCHEMBL8749067 | 0.74 | TSHR (0.52) | SMN1; SMN2USP2TSHRPKMRECQL | |
| SCHEMBL8749267 | 0.74 | TSHR (0.52) | SMN1; SMN2USP2TSHRPKMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | SMN1; SMN2 4641/4885USP2 2263/4885TSHR 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.